SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca announced that the Phase III SERENA-4 trial of Etcamah…

ASTRAZENECA PLC · 6-K filed Sep 14, 2026 at 07:36 ET

At the news

BEARISHIMPACT 5/10

6-K filed Sep 14, 2026 at 07:36 ET

AstraZeneca announced that the Phase III SERENA-4 trial of Etcamah (camizestrant) plus palbociclib in 1st-line advanced ER+/HER2- breast cancer did not meet its primary endpoint of statistically significant improvement in progression-free survival, though a numerical improvement was observed. This is a negative read for the Etcamah franchise's potential in the broader 1st-line setting, but Etcamah remains approved in the US/EU/Japan for ESR1-mutant patients based on the SERENA-6 trial, and the ongoing CAMBRIA-1/2 adjuvant trials (approx. 10,000 patients) provide a separate long-term opportunity. The stock impact is likely modest given AZN's diversified pipeline and the fact that the SERENA-6 label already covers the key ESR1-mutant indication.

  • SERENA-4 Phase III trial of Etcamah + palbociclib did not meet primary endpoint of statistically significant PFS improvement in 1st-line advanced ER+/HER2- breast cancer.
  • A numerical improvement in PFS was observed, but the trial failed to show statistical significance versus anastrozole + palbociclib.
  • Etcamah remains approved in the US, EU, Japan, and other countries for ESR1-mutant advanced breast cancer based on the SERENA-6 trial.
  • The CAMBRIA-1 and CAMBRIA-2 Phase III adjuvant trials (approx. 10,000 patients) are ongoing and represent the broader early-breast-cancer opportunity.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access